Nkarta Advances NKX019 to 12 Billion-Cell Cycle, Secures $295M Runway
Nkarta advanced NKX019 dose escalation to 4 billion cells per infusion (12 billion per cycle) in its Ntrust-1 and Ntrust-2 autoimmune trials. The company reported $295.1 million in cash, cash equivalents and investments as of December 31, 2025, funding operations into 2029 with initial data set for a 2026 conference.
1. Clinical Dose Escalation Progress
Nkarta has escalated NKX019 dosing to 4 billion cells per infusion on days 0, 3 and 7 (12 billion total per cycle) in its multi-center Ntrust-1 and Ntrust-2 trials in autoimmune diseases such as myasthenia gravis and lupus. Enrollment remains open across dose levels in generalized myasthenia gravis, systemic lupus erythematosus and other indications.
2. Financial Position and Runway
As of December 31, 2025, Nkarta held $295.1 million in cash, cash equivalents and investments, with projections indicating funding to sustain operations into 2029. Full-year R&D expenses reached $90.4 million and G&A expenses totaled $31.6 million, resulting in a net loss of $104.1 million for 2025.
3. Upcoming Data Presentation
Initial clinical data from the Ntrust-1 and Ntrust-2 trials are slated for presentation at a medical conference in 2026, offering the first comprehensive look at NKX019’s safety and B‐cell depletion efficacy. The company plans disciplined enrollment and execution to support regulatory discussions.